Last €12.06 EUR
Change Today +0.301 / 2.56%
Volume 0.0
ITH On Other Exchanges
As of 12:09 PM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

nektar therapeutics (ITH) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/24/14 - €12.10
52 Week Low
04/15/14 - €7.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEKTAR THERAPEUTICS (ITH)

nektar therapeutics (ITH) Related Businessweek News

No Related Businessweek News Found

nektar therapeutics (ITH) Details

Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company’s drug candidates in clinical development stage comprise naloxegol, an opioid antagonist, which has completed Phase III clinical trial for treating opioid-induced constipation; BAY41-6551 that is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181, which has completed Phase II clinical trial for chronic pain; and NKTR-171 that is in Phase I clinical trial to treat neuropathic pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase III clinical trial for metastatic breast cancer and in Phase II clinical trial for second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that has completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 to treat chronic pain; NKTR-192 to treat acute pain; and NKTR-214, a cytokine immunostimulatory therapy to treat oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551, which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB to develop and commercialize naloxegol and naloxegol fixed-dose combination program. Further, it has license, manufacturing, and supply agreements with Amgen Inc.; MAP Pharmaceuticals, Inc.; Merck & Co., Inc.; Ophthotech Corporation; Pfizer, Inc.; F. Hoffmann-La Roche Ltd (Roche), Regado Biosciences, Inc.; and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

445 Employees
Last Reported Date: 02/27/14
Founded in 1990

nektar therapeutics (ITH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $831.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $524.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $504.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $459.7K
Compensation as of Fiscal Year 2013.

nektar therapeutics (ITH) Key Developments

Nektar Therapeutics Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with PARP Inhibitor in BRCA1-Deficient Cancer Model

Nektar Therapeutics announced results of a study investigating the preclinical anti-tumor activity and tolerability of etirinotecan pegol (NKTR-102) in combination with the PARP inhibitor rucaparib in a BRCA1-deficient MX-1 breast tumor model. The preclinical study results demonstrated that all dose combinations of NKTR-102 and rucaparib were well-tolerated, synergistic, and led to 100% prolonged survival in this tumor model. These data were presented during the Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, sponsored by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR). NKTR-102 is the first long-acting topoisomerase I inhibitor with an extended half-life and a unique structure that is also designed to concentrate the drug in tumors. In patients, NKTR-102 leads to greatly prolonged plasma SN38 exposure compared to irinotecan (elimination half-life of 50 days compared to 2 days) yet peak SN38 concentrations are at least 5- to 10-times less, which may also result in a favorable tolerability profile. Study investigators initiated tumor xenografts with MX-1 human breast carcinomas maintained by serial subcutaneous transplantation in female athymic nude (Crl:NU(Ncr)-Foxn1nu), 8-week-old mice. On the day of tumor implant, each test mouse received a 1-mm(3) MX-1 fragment implanted subcutaneously in the right flank. Animals were randomized into treatment groups (n=10/grp) when their tumors reached 63-196 mm(3) and subsequently received either vehicle, NKTR-102, rucaparab, or combinations of NKTR-102 + rucaparib. Doses selected were known to provide clinically relevant exposure levels. Twice weekly, animals were weighed, and tumor volumes were measured until the endpoint (2,000 mm(3) or Day 88) was met. Efficacy was measured by tumor growth delay and regression response rate. NKTR-102 and rucaparib in combination exhibited marked synergy, demonstrated by durable complete responses, even at the lowest doses of both agents dosed in combination. The combination of NKTR-102 and rucaparib was tolerated at all dose levels. Doses used in this study provide exposures of NKTR-102 (SN38 trough) and rucaparib that are achievable clinically, underscoring the translational relevance of these Combination studies of NKTR-102 and rucaparib are ongoing in patient-derived xenograft models in collaboration with Professor Paul Haluska at Mayo Clinic and Clovis Oncology.

Nektar Therapeutics Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Nektar Therapeutics reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $132,871,000 against $60,909,000 a year ago. Income from operations was $80,321,000 against loss from operations of $6,525,000 a year ago. Income before provision for income taxes was $70,853,000 against loss before provision for income taxes of $16,350,000 a year ago. Net income was $70,605,000 against net loss of $16,543,000 a year ago. Diluted net earnings per share were $0.53 against basic and diluted loss per share of $0.14 a year ago. For the nine months, the company reported total revenue of $181,155,000 against $117,775,000 a year ago. Income from operations was $21,003,000 against loss from operations of $84,236,000 a year ago. Loss before provision for income taxes was $7,599,000 against $113,744,000 a year ago. Net loss was $8,233,000 against $114,354,000 a year ago. Basic and diluted net loss per share was $0.07 against $0.99 a year ago. Net cash used in operating activities was $117,379,000 against $92,158,000 a year ago. Purchases of property and equipment were $6,090,000 against $1,382,000 a year ago. Revenue increased in the third quarter and first nine months of 2014 as compared to the same periods in 2013 primarily due to $105.0 million in milestones recognized in September 2014 upon the approval of MOVANTIK in the U.S., of which $70.0 million was received in November 2013. These increases in revenue in 2014 were partially offset by a $25.0 million milestone payment recognized in September 2013 upon the acceptance of the MOVANTIK EMA regulatory application.

Nektar Therapeutics to Report Q3, 2014 Results on Nov 06, 2014

Nektar Therapeutics announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Nov 06, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITH:GR €12.06 EUR +0.301

ITH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $15.59 USD +0.13
Emergent Biosolutions Inc $25.00 USD +0.44
Ironwood Pharmaceuticals Inc $13.78 USD -0.06
Synergy Health PLC 1,915 GBp +16.00
Theravance Inc $15.20 USD +1.23
View Industry Companies

Industry Analysis


Industry Average

Valuation ITH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.8x
Price/Book 39.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at